Steris Plc (STE) Stock Price & Analysis
Steris Plc (STE) rose 1.36% to USD 212.88 as of June 9, 2026 at 23:43 UTC, according to Nexqual real-time market data.
STE last closed at USD 210.03; the session ranged USD 211.26–214.38 on volume of 661,891 shares. Market capitalization is $20.78B, with a 52-week range of USD 195.14–269.44 (NYQ). Source: Nexqual, June 9, 2026 at 23:43 UTC.
Key Statistics (as of June 9, 2026 at 23:43 UTC)
| Price | USD 212.88 |
|---|---|
| Change | ▲ 1.36% (up) |
| Previous Close | USD 210.03 |
| Open | USD 211.59 |
| Day Range | USD 211.26 – 214.38 |
| 52-Week Range | USD 195.14 – 269.44 |
| Volume | 661,891 shares |
| Market Cap | $20.78B |
| Exchange | NYQ |
Technical Analysis (STE)
Nexqual's technical model rates STE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.9 (neutral) |
| vs SMA50 | Below (USD 216.71) |
| MACD | -1.46 (negative) |
Analyst Ratings (STE)
Wall Street analysts rate STE "Buy" based on 7 analysts, with a mean price target of USD 256.86 (range USD 225–280), per Nexqual as of June 9, 2026 at 23:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 256.86 |
| High Target | USD 280 |
| Low Target | USD 225 |
| Buy / Hold / Sell | 6 / 2 / 0 |
Earnings (STE)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.5 |
| Revenue Estimate | $1.50B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.83 vs est 2.85 ▼ miss |
| 2025-12-31 | USD 2.53 vs est 2.53 ▼ miss |
| 2025-09-30 | USD 2.47 vs est 2.35 ▲ beat |
| 2025-06-30 | USD 2.34 vs est 2.26 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Financials & Fundamentals (STE)
| Total Revenue | $5.94B |
|---|---|
| Revenue Growth (YoY) | +7.30% |
| Gross Margin | +44.24% |
| Operating Margin | +20.04% |
| Profit Margin | +13.18% |
| ROE | +11.37% |
| Debt / Equity | 29 |
| Current Ratio | 2.09 |
| Total Cash | $439.60M |
| Total Debt | $2.09B |
| Free Cash Flow | $837.29M |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Financial Health Score (STE)
Nexqual rates Steris Plc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:43 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 20% |
| Balance Sheet | Strong — $440M cash vs $2.09B debt |
| Cash Flow | Solid — FCF $837M, 14% margin |
| Efficiency | Mixed — ROE 11%, ROA 6.7% |
Ownership (STE)
| Insider Ownership | +0.32% |
|---|---|
| Institutional Ownership | +100.65% |
| Shares Outstanding | 97.60M |
| Float | 97.18M |
| Short % of Float | +2.54% |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
Leadership (STE)
Steris Plc is led by Daniel A. Carestio (age 52), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:43 UTC.
| President, CEO & Director | Daniel A. Carestio (age 52) |
|---|---|
| Senior VP & President of Healthcare | Cary L. Majors (age 50) |
| Senior VP, CFO & Chief Accounting Officer | Karen L. Burton (age 57) |
| Vice President of Investor Relations & Corporate Communications | Julie Winter |
Major Backers & Investors (STE)
Notable institutional backers of Steris Plc include Morgan Stanley, Massachusetts Financial Services Co., Wellington Management, according to Nexqual as of June 9, 2026 at 23:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 4.5% |
| Massachusetts Financial Services Co. | 4.11% |
| Wellington Management | 2.94% |
| Orbis Allan Gray Ltd | 2.66% |
| Generation Investment Management LLP | 2.37% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.47% |
| BlackRock | 10.55% |
| State Street | 6.32% |
| Geode Capital | 2.65% |
Source: Nexqual, June 9, 2026 at 23:43 UTC.
From Steris Plc's Latest SEC 10-K Filing (filed 2026-05-29)
Key Strengths & Strategy (as disclosed to the SEC)
- STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.
- It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.
- It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting.
- In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:43 UTC. This page is informational and not investment advice.